Relevance of histone marks H3K9me3 and H4K20me3 in cancer

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 2199-2206

  Leszinski, Gloria ^a   Gezer, Ugur ^b   Siegele, Barbara ^a   Stoetzer, Oliver ^c   Holdenrieder, Stefan ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Haematology and Oncology Outpatient Cancer Care Center Munich   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Breast cancer; Circulating nucleosomes; Colorectal cancer; Histone methylation; Histone modification; SAT2 repeats; Serum; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HISTONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CENTROMERE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; INFLAMMATORY DISEASE; LUNG CANCER; MALE; NUCLEOSOME; PANCREAS CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC;

ACETYLTRANSFERASES; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HISTONES; HUMANS; MALE; METHYLATION; MIDDLE AGED; NEOPLASMS; NUCLEOSOMES; TUMOR MARKERS, BIOLOGICAL;

EID: 84861496074     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Holdenrieder S, Stieber P, Bodenmueller H, Busch M, Fertig G, Fuerst H, Schalhorn A, Schmeller N, Untch M and Seidel D: Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 95: 114-120, 2001. (Pubitemid 32187083)
2. Holdenrieder S and Stieber P: Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci 46: 1-24, 2009.
3. Geiger S, Holdenrieder S, Stieber P, Hamann GF, Brüning R, Ma J, Nagel D and Seidel D: Nucleosomes in serum of patients with early cerebral stroke. Cerebro Vasc Dis 21: 32-37, 2006. (Pubitemid 43110307)
4. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van Mierlo GJ, Eerenberg AJ, Lammle B and Hack CE: Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 31: 1947-1951, 2003. (Pubitemid 36900748)
5. Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Schoenermarck U, Zachoval R, Nagel D and Stieber P: Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci 1075: 318-327, 2006. (Pubitemid 44532800)
6. Holdenrieder S and Stieber P: Therapy control in oncology by circulating nucleosomes. Ann NY Acad Sci 1022: 211-216, 2004. (Pubitemid 38951604)
7. Kuroi K, Tanaka C and Toi M: Clinical significance of plasma nucleosomes levels in cancer patients. Int J Oncol 19: 143-148, 2001.
8. Holdenrieder S, Stieber P, v Pawel J, Raith H, Nagel D, Feldmann K and Seidel D: Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 10: 5981-5987, 2004. (Pubitemid 39287502)
9. Mueller S, Holdenrieder S, Stieber P, Haferlach T, Nagel D and Seidel D: Early prediction of therapy response in patients with acute myeloid leukaemia by nucleosomal DNA fragments. BMC Cancer 6: 143, 2006.
10. Holdenrieder S, Holubec L jr, Topolcan O, Finek J and Stieber P: Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res 25: 1795-1802, 2005.
11. Kremer A, Holdenrieder S, Stieber P, Wilkowski R, Nagel D and Seidel D: Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumor Biol 27: 235-242, 2006. (Pubitemid 44260248)
12. Kremer A, Wilkowski R, Holdenrieder S, Nagel D, Stieber P and Seidel D: Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol 26: 44-49, 2005. (Pubitemid 40529297)
13. Holdenrieder S, Stieber P, v Pawel J, Raith H, Nagel D, Feldmann K and Seidel D: Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann NY Acad Sci 1075: 244-257, 2006. (Pubitemid 44532791)
14. Holdenrieder S, v Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D and Stieber P: Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 63: 128-135, 2009.
15. Holdenrieder S, v Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D and Stieber P: Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res 14: 7813-7821, 2008.
16. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A and Das BC: Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 11: 36-44, 2010.
17. Luger K: Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev 13: 127-135, 2003.
18. Kornberg RD and Lorch Y: Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98: 285-294, 1999. (Pubitemid 29380564)
19. Munshi A, Shafi G, Aliya N and Jyothy A: Histone modifications dictate specific biological readouts. J Genet Genomics 36: 75-88, 2009.
20. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403: 41-45, 2000. (Pubitemid 30038513)
21. Turner BM: Histone acetylation and an epigenetic code. Bioessays 22: 836-845, 2000.
22. Barth TK and Imhof A: Fast signals and slow marks: the dynamics of histone modifications. Trends Biochem Sci 35: 618-626, 2010.
23. Lehnertz B, Ueda Y, Derijck AA, Braunschweig U, Perez-Burgos L, Kubicek S, Chen T, Li E, Jenuwein T and Peters AH: Suv39hmediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 13: 1192-1200, 2003. (Pubitemid 36872941)
24. Peters AH, Kubicek S, Mechtler K, O'Sullivan RJ, Derijck AA, Perez-Burgos L, Kohlmaier A, Opravil S, Tachibana M, Shinkai Y, Martens JH and Jenuwein T: Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell 12: 1577-1589, 2003. (Pubitemid 38037024)
25. Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, Shinkai Y and Allis CD: Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 12: 1591-1598, 2003. (Pubitemid 38037025)
26. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D and Jenuwein T: A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 18: 1251-1262, 2004. (Pubitemid 38720593)
27. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T and Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 7: 391-400, 2005.
28. Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W, Bastian PJ, Büttner R, Müller SC and von Rücker A: Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 127: 2360-2366, 2010.
29. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Büttner R, Müller SC, Bastian PJ and von Rücker A: Global levels of histone modifications predict prostate cancer recurrence. Prostate 70: 61-69, 2010.
30. Schneider AC, Heukamp LC, Rogenhofer S, Fechner G, Bastian PJ, von Rücker A, Müller SC and Ellinger J: Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int 108: E290-296, 2011.
31. Rogenhofer S, Kahl P, Mertens C, Hauser S, Hartmann W, Büttner R, Müller SC, von Rücker A and Ellinger J: Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int 109: 459-465, 2012.
32. Deligezer U, Akisik EE, Erten N and Dalay N: Sequencespecific histone methylation is detectable on circulating nucleosomes in plasma. Clin Chem 54: 1125-1131, 2008. (Pubitemid 352009688)
33. Deligezer U, Akisik EZ, Akisik EE, Kovancilar M, Bugra D, Erlen N, Holdenrieder S and Dalay N: H3K9me3/H4K20me3 ratio in circulating nucleosomes as potential biomarker for colorectal cancer. In: Circulating Nucleic Acids in Plasma and Serum, Gahan P. Springer, Heidelberg, 1st Edition: pp. 97-103, 2011.
34. Deligezer U, Yaman F, Darendeliler E, Dizdar Y, Holdenrieder S, Kovancilar M and Dalay N: Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta 411: 1452-1456, 2010.
35. Alexiadis V, Ballestas ME, Sanchez C, Winokur S, Vedanarayanan V, Warren M and Ehrlich M: RNAPol-ChIP analysis of transcription from FSHD-linked tandem repeats and satellite DNA. Biochim Biophys Acta 1769: 29-40, 2007. (Pubitemid 46149924)
36. Holdenrieder S, Stieber P, Bodenmueller H, Fertig G, Fuerst H, Schmeller N, Untch M and Seidel D: Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 39: 596-605, 2001. (Pubitemid 32725743)
37. Rodríguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339, 2011.
38. Scharf AN and Imhof A: Every methyl counts - epigenetic calculus. FEBS Lett 585: 2001-2007, 2011.
39. Martens JH, O'Sullivan RJ, Braunschweig U, Opravil S, Radolf M, Steinlein P and Jenuwein T: The profile of repeat-associated histone lysine methylation states in the mouse epigenome. EMBO J 24: 800-812, 2005. (Pubitemid 40396109)
40. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, v Pawel J, Raith H, Feldmann K, Kremer A, Müller S, Geiger S, Hamann GF, Seidel D and Stieber P: Clinical relevance of circulating nucleosomes in cancer. Ann NY Acad Sci 1137: 180-189, 2008.